Found: 460
Select item for more details and to access through your institution.
Subcortical Structures and Neuropsychiatric Illness.
- Published in:
- Neuroscientist, 1996, v. 2, n. 1, p. 66, doi. 10.1177/107385849600200114
- By:
- Publication type:
- Article
Anatomic and Behavioral Aspects of Frontal-Subcortical Circuitsa.
- Published in:
- Annals of the New York Academy of Sciences, 1995, v. 769, n. 1, p. 1, doi. 10.1111/j.1749-6632.1995.tb38127.x
- By:
- Publication type:
- Article
Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia.
- Published in:
- Movement Disorders, 2010, v. 25, n. 6, p. 687, doi. 10.1002/mds.22799
- By:
- Publication type:
- Article
Clinical diagnostic criteria for dementia associated with Parkinson's disease.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH Work Group.
- Published in:
- Movement Disorders, 2006, v. 21, n. 2, p. 148, doi. 10.1002/mds.20723
- By:
- Publication type:
- Article
Neuropsychiatric assessment of Gilles de la Tourette patients: Comparative study with other hyperkinetic and hypokinetic movement disorders.
- Published in:
- Movement Disorders, 2001, v. 16, n. 6, p. 1098, doi. 10.1002/mds.1225
- By:
- Publication type:
- Article
Traditional dentistry versus retail dentistry: a sociological pilot study of the dental profession.
- Published in:
- Quintessence International, 1985, v. 16, n. 9, p. 651
- By:
- Publication type:
- Article
Effect of Donepezil on Cognition in Severe Alzheimer's Disease: A Pooled Data Analysis.
- Published in:
- Journal of Alzheimer's Disease, 2010, v. 21, n. 3, p. 843, doi. 10.3233/JAD-2010-100078
- By:
- Publication type:
- Article
PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses.
- Published in:
- Journal of Alzheimer's Disease, 2010, v. 20, n. 2, p. 509, doi. 10.3233/JAD-2010-1390
- By:
- Publication type:
- Article
Effects of Rivastigmine in Alzheimer's Disease Patients with and Without Hallucinations.
- Published in:
- Journal of Alzheimer's Disease, 2010, v. 20, n. 1, p. 301, doi. 10.3233/JAD-2010-1362
- By:
- Publication type:
- Article
Mary S. Easton Center of Alzheimer's Disease Research at UCLA: Advancing the Therapeutic Imperative.
- Published in:
- Journal of Alzheimer's Disease, 2010, v. 19, n. 2, p. 375, doi. 10.3233/JAD-2010-1286
- By:
- Publication type:
- Article
Rivastigmine Transdermal Patch Skin Tolerability: Results of a 1-Year Clinical Trial in Patients with Mild-to-Moderate Alzheimer's Disease.
- Published in:
- Clinical Drug Investigation, 2010, v. 30, n. 1, p. 41, doi. 10.2165/11531270-000000000-00000
- By:
- Publication type:
- Article
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
- Published in:
- Alzheimer's Research & Therapy, 2022, p. 1, doi. 10.1186/s13195-022-01124-2
- By:
- Publication type:
- Article
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease.
- Published in:
- Alzheimer's Research & Therapy, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13195-022-01110-8
- By:
- Publication type:
- Article
RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus.
- Published in:
- Alzheimer's Research & Therapy, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13195-022-01103-7
- By:
- Publication type:
- Article
RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus.
- Published in:
- Alzheimer's Research & Therapy, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13195-022-01103-7
- By:
- Publication type:
- Article
Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
The role of basket trials in drug development for neurodegenerative disorders.
- Published in:
- Alzheimer's Research & Therapy, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13195-022-01015-6
- By:
- Publication type:
- Article
Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease.
- Published in:
- Alzheimer's Research & Therapy, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13195-022-00984-y
- By:
- Publication type:
- Article
Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease.
- Published in:
- Alzheimer's Research & Therapy, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13195-021-00951-z
- By:
- Publication type:
- Article
The Alzheimer's disease drug development landscape.
- Published in:
- Alzheimer's Research & Therapy, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13195-021-00927-z
- By:
- Publication type:
- Article
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.
- Published in:
- Alzheimer's Research & Therapy, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13195-021-00838-z
- By:
- Publication type:
- Article
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
- Published in:
- Alzheimer's Research & Therapy, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13195-021-00813-8
- By:
- Publication type:
- Article
Montreal Cognitive Assessment (MoCA) XpressO: Validation of a digital self‐administered cognitive prescreening tool.
- Published in:
- Journal of the American Geriatrics Society, 2024, v. 72, n. 8, p. 2516, doi. 10.1111/jgs.18902
- By:
- Publication type:
- Article
Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing.
- Published in:
- Medicinal Research Reviews, 2020, v. 40, n. 6, p. 2386, doi. 10.1002/med.21709
- By:
- Publication type:
- Article
Topological reorganization of functional hubs in patients with Parkinson's disease with freezing of gait.
- Published in:
- Journal of Neuroimaging, 2023, v. 33, n. 4, p. 547, doi. 10.1111/jon.13107
- By:
- Publication type:
- Article
Using bibliometrics to evaluate outcomes and influence of translational biomedical research centers.
- Published in:
- Journal of Clinical & Translational Science, 2022, v. 6, n. 1, p. 1, doi. 10.1017/cts.2021.863
- By:
- Publication type:
- Article
Disease modification and Neuroprotection in neurodegenerative disorders.
- Published in:
- Translational Neurodegeneration, 2017, v. 6, p. 1, doi. 10.1186/s40035-017-0096-2
- By:
- Publication type:
- Article
Cortical Change in Alzheimer's Disease Detected with a Disease-specific Population-based Brain Atlas.
- Published in:
- Cerebral Cortex, 2001, v. 11, n. 1, p. 1, doi. 10.1093/cercor/11.1.1
- By:
- Publication type:
- Article
CONCLUDING REMARKS.
- Published in:
- Drugs & Aging, 2005, v. 22, p. 39, doi. 10.2165/00002512-200522001-00004
- By:
- Publication type:
- Article
FOREWORD.
- Published in:
- Drugs & Aging, 2005, v. 22, p. 7
- By:
- Publication type:
- Article
Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification.
- Published in:
- Drugs, 2023, v. 83, n. 15, p. 1387, doi. 10.1007/s40265-023-01938-w
- By:
- Publication type:
- Article
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics.
- Published in:
- Drugs, 2023, v. 83, n. 7, p. 569, doi. 10.1007/s40265-023-01858-9
- By:
- Publication type:
- Article
Fluid biomarkers in clinical trials of Alzheimer's disease therapeutics.
- Published in:
- Frontiers in Neurology, 2015, p. 1, doi. 10.3389/fneur.2015.00186
- By:
- Publication type:
- Article
Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume.
- Published in:
- Alzheimer's Research & Therapy, 2017, v. 9, p. 1, doi. 10.1186/s13195-017-0300-8
- By:
- Publication type:
- Article
On the path to 2025: understanding the Alzheimer's disease continuum.
- Published in:
- Alzheimer's Research & Therapy, 2017, v. 9, p. 1, doi. 10.1186/s13195-017-0283-5
- By:
- Publication type:
- Article
Drug development in Alzheimer's disease: the path to 2025.
- Published in:
- Alzheimer's Research & Therapy, 2016, v. 8, p. 1, doi. 10.1186/s13195-016-0207-9
- By:
- Publication type:
- Article
Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.
- Published in:
- Alzheimer's Research & Therapy, 2016, v. 8, p. 1, doi. 10.1186/s13195-016-0173-2
- By:
- Publication type:
- Article
Alzheimer's disease progression by geographical region in a clinical trial setting.
- Published in:
- Alzheimer's Research & Therapy, 2015, v. 7, n. 1, p. 1, doi. 10.1186/s13195-015-0127-0
- By:
- Publication type:
- Article
Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials.
- Published in:
- Alzheimer's Research & Therapy, 2015, v. 7, n. 1, p. 1, doi. 10.1186/s13195-015-0122-5
- By:
- Publication type:
- Article
Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch.
- Published in:
- Alzheimer's Research & Therapy, 2015, v. 7, n. 1, p. 1, doi. 10.1186/s13195-014-0088-8
- By:
- Publication type:
- Article
Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study.
- Published in:
- Alzheimer's Research & Therapy, 2012, v. 4, n. 5, p. 43, doi. 10.1186/alzrt146
- By:
- Publication type:
- Article
Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity.
- Published in:
- Alzheimer's Research & Therapy, 2013, v. 5, n. 1, p. 1, doi. 10.1186/alzrt166
- By:
- Publication type:
- Article
Globalization of Alzheimer's disease clinical trials.
- Published in:
- Alzheimer's Research & Therapy, 2011, v. 3, n. 4, p. 1, doi. 10.1186/alzrt86
- By:
- Publication type:
- Article
Comparison of neuropsychological functioning in Alzheimer's disease and frontotemporal dementia.
- Published in:
- Journal of the International Neuropsychological Society, 1996, v. 2, n. 6, p. 505, doi. 10.1017/S1355617700001673
- By:
- Publication type:
- Article
BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
- Published in:
- 2020
- By:
- Publication type:
- journal article
The A431E mutation in PSEN1 causing Familial Alzheimer’s Disease originating in Jalisco State, Mexico: an additional fifteen families.
- Published in:
- Neurogenetics, 2006, v. 7, n. 4, p. 277, doi. 10.1007/s10048-006-0053-1
- By:
- Publication type:
- Article
Health-related quality-of-life and service utilization in Alzheimer's disease: A cross-sectional study.
- Published in:
- American Journal of Alzheimer's Disease & Other Dementias, 2000, v. 15, n. 2, p. 94, doi. 10.1177/153331750001500206
- By:
- Publication type:
- Article